检索结果-南通市图书馆

第四届中国肿瘤学术大会暨第五届海峡两岸肿瘤学术会议

作者： Isma■l hervé Koumakpayi Cécile Le Page Laurent Lessard Jean-Simon Diallo Philippe O. Gannon Benjamin Péant Nathalie Delvoye Anne-Marie Mes-Masson fred saad chum-höpital notre-dame Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada Institut du cancer de Montréal 1560 rue Sherbrooke Est MontréalQuébecH2L 4M1Canada

＜正＞Background and Aims: The treatment of prostate cancer （PCa） depends on stage. To improve treatment strategies, it would be helpful to have reliable molecular markers able to predict PCa progression. however, to date, such markers have not yet been included in therapeutic decisions. Recently, several studies from our laboratory described the prognostic potential of molecular markers that include ErbB3, Akt and Nuclear Factor kappaB （NF- κB） . ErbB3 is a member of the growth factor receptor family ErbB. Akt is a signaling component of the ErbB receptor family. Phos-phoinositol 3 - kinase （PI3K） through Akt regulates downstream signaling proteins such as NF - κB. Most of these molecules are often overexpressed and/or activated in cancer cells. Furthermore, they can be detected in the cytoplasm and/or nucleus of PCa cells. They are known to be involved in cell survival, cell growth, cell cycle progression and apoptotic response. The aim of our study was to determine whether these molecules could be used as markers to predict PCa progression.

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

The association of type and number of high-risk criteria with cancer-specific mortality in prostate cancer patients treated with radical prostatectomy

引用

Current Urology 2024年第2期18卷 128-132页

作者： Francesco Chierigo Rocco Simone Flammia GabrieleSorce Benedikt hoeh Lukas hohenhorst Andrea Panunzio Zhe Tian fred saad Marcus Graefen Michele Gallucci Alberto Briganti Francesco Montorsi Felix K.h.Chun Shahrokh F.Shariat Alessandro Antonelli Giovanni Guano Guglielmo Mantica Marco Borghesi Nazareno Suardi Carlo Terrone Pierre I.Karakiewicz Department of Surgical and Diagnostic Integrated Sciences University of GenovaGenovaItaly IRCCS Ospedale Policlinico San Martino GenovaItaly Cancer Prognostics and health Outcomes Unit Division of UrologyUniversity ofMontréal Health CenterMontréalQuébecCanada Department of Urology IRCCS Policlinico San MartinoGenovaItaly Department of Maternal-Child and Urological Sciences Sapienza Rome UniversityPoliclinico Umberto I HospitalRomeItaly Department of Urology University Hospital FrankfurtFrankfurt am MainGermany Martini-Klinik Prostate Cancer Center University Hospital Hamburg-EppendorfHamburgGermany Department of Urology University of VeronaAzienda Ospedaliera Universitaria Integrata di VeronaVeronaItaly Division of Experimental Oncology/Unit of Urology URIUrological Research InstituteIRCCS San Raffaele Scientific InstituteMilanItaly Department of Urology Comprehensive Cancer CenterMedical University of ViennaViennaAustria Department of Urology Weill Cornell Medical CollegeNew YorkNYUSA Department of Urology University of Texas SouthwesternDallasTXUSA Department of Urology Second Faculty of MedicineCharles UniversityPragueCzech Republic Institute for Urology and Reproductive health I.M.Sechenov First Moscow State Medical UniversityMoscowRussia Division of Urology Department of Special SurgeryJordan University HospitalThe University of JordanAmmanJordan

Objectives:This study aimed to test the association between of type and number of D'Amico high-risk criteria(DhRCs)with cancer-specific mortality(CSM)in high-risk prostate cancer patients treated with radical *** and methods:In the Surveillance,Epidemiology,and End Results database(2004–2016),we identified 31,281 radical prostatectomy patients with at least 1 DhRC,namely,prostate-specific antigen(PSA)>20 ng/mL(hrPSA),biopsy Gleason Grade Group(hrGGG)score of 4 and 5,or clinical tumor stage≥T3(hrcT).Multivariable Cox regression models and competing risks regression models(adjusting for other cause mortality)tested the association between DhRCs and 5-year ***:Of 31,281 patients,14,394(67%)exclusively harbored hrGGG,3189(15%)harbored hrPSA,and 1781(8.2%)harbored *** 2132 patients(6.8%)harbored a combination of the 2 DhRCs,and 138(0.6%)had all 3 ***-year CSMrates ranged from 0.9%to 3.0%when any individual DhRC was present(hrcT,hrPSA,and hrGGG,in that order),1.6%to 5.9%when 2 DhRCs were present(hrPSA-hrcT,hrcT-hrGGG,and hrPSA-hrGGG,in that order),and 8.1%when all 3 DhRCs were *** regression models and competing risks regression confirmed the independent predictor status of DhRCs for 5-year CSM that was observed in univariable analyses,with hazard ratios from 1.00 to 2.83 for 1 DhRC,2.35 to 5.88 for combinations of 2 DhRCs,and 7.13 for all 3 ***:Within individual DhRCs,hrcT and hrPSA exhibited weaker effects than hrGGG ***,a dose-response effect was identified according to the number of ***,the type and number of DhRCs allow further risk stratification within the high-risk subgroup.

关键词： high risk prostate cancer Radical prostatectomy Cancer-specific mortality Staging SEER

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Primary lymphomas of the genitourinary tract:A population-based study

引用

Asian Journal of Urology 2020年第4期7卷 332-339页

作者： Carlotta Palumbo Elio Mazzone Francesco A.Mistretta Sophie Knipper Zhe Tian Paul Perrotte Francesco Montorsi Shahrokh F.Shariat fred saad Claudio Simeone Alberto Briganti Alessandro Antonelli Pierre I.Karakiewicz Cancer Prognostics and health Outcomes Unit University of Montreal Health CenterMontrealQuebecCanada Urology Unit ASST Spedali Civili of BresciaDepartment of Medical and Surgical SpecialtiesRadiological Science and Public HealthUniversity of BresciaBresciaItaly Division of Experimental Oncology Unit of UrologyUrological Research Institute(URI)IRCCS San Raffaele Scientific InstituteMilanItaly Vita-Salute San Raffaele University MilanItaly Department of Urology European Institute of OncologyMilanItaly Martini Klinik University Medical Center Hamburg-EppendorfHamburgGermany Division of Urology University of Montreal Hospital Center(CHUM)MontrealQuebecCanada Department of Urology Comprehensive Cancer CenterMedical University of ViennaViennaAustria Department of Urology Weill Cornell Medical CollegeNew YorkNYUSA Department of Urology University of Texas SouthwesternDallasTXUSA Department of Urology Second Faculty of MedicineCharles UniversityPragCzech Republic Institute for Urology and Reproductive health I.M.Sechenov First Moscow State Medical UniversityMoscowRussia

Objective:We performed a population-based analysis focusing on primary extranodal lymphoma of either testis,kidney,bladder or prostate(PGUL).Methods:We identified all cases of localized testis,renal,bladder and prostate primary lymphomas(PL)versus primary testis,kidney,bladder and prostate cancers within the Surveillance,Epidemiology,and End Results database(1998e2015).Estimated annual proportion change methodology(EAPC),multivariable logistic regression models,cumulative incidence plots and multivariable competing risks regression models were ***:The rates of testis-PL,renal-PL,bladder-PL and prostate-PL were 3.04%,0.22%,0.18%and 0.01%,*** with PGUL were older and more frequently *** rates significantly decreased for renal-PL(EAPC:5.6%;pZ0.004)and prostate-PL(EAPC:3.6%;pZ0.03).In multivariable logistic regression models,older ager independently predicted testis-PL(odds ratio[OR]:16.4;phile female gender independently predicted bladder-PL(OR:5.5;phowed significantly higher 10-year cancer-specific mortality(CSM)rates for testis-PL,renal-PL and prostate-PL versus their primary genitourinary *** multivariable competing risks regression models,only testis-PL(hazard ratio[hR]:16.7;phR:2.52;phigher CSM ***:PGUL rates are extremely low and on the decrease in kidney and prostate but stable in testis and *** to primary genitourinary tumors,PGUL are associated with worse CSM for testis-PL and renal-PL but not for bladder-PL and prostate-PL,even after adjustment for other-cause mortality.

关键词： Bladder lymphoma Genitourinary neoplasm Genitourinary Primary extranodal lymphoma Prostate lymphoma Renal lymphoma Testis lymphoma Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：